Telix Pharmaceuticals Ltd — Director's Dealing 2025

Mar 6, 2025

Appendix 3Y Change of Director’s Interest Notice

Rule 3.19A.2

Appendix 3Y

Change of Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity Telix Pharmaceuticals Limited ABN 85 616 620 369

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Marie McDonald
Date of last notice	3 March 2025

Part 1 - Change of director’s relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

Part 1 - Change of dIn the case of a trust, this	Part 1 - Change of dIn the case of a trust, this	irector’s relevant interests in securitiesincludes interests in the trust made available by the responsib	irector’s relevant interests in securitiesincludes interests in the trust made available by the responsib	le entity of the trust	le entity of the trust
Note: In the case of a compadisclosed in this part.Direct or indirect iNature of indirect(including registerNt Pid dtil f t		ny, interests which come within paragraph (i) of the definition of “notif		iable interest of a director” should be
	Direct or indirect i	nterest	Indirect interest
	Nature of indirect(including registerNt Pid dtil f t	interested holder)it ii i t th lt	Netwealth InvesMarie Elizabeth	tments Limited as custodian fMcDonald
	oe: rove eas o e crcumsances gvng rse o e reevaninterest.
	Date of change		5 March 2025
	No. of securities held prior to change		Nil
	Class		Fully paid ordinary shares
	Number acquired		3,719
	Number disposed		Nil
	Value/ConsiderationNote: If consideration is non-cash, provide details and estimatedvaluation		Average price of $26.91 per share
	No. of securities held after change		3,719 fully paid ordinary shares
	Nature of changeExample: on-market trade, off-market trade, exercise of options, issueof securities under dividend reinvestment plan, participation in buy-back		On-market trade

• See chapter 19 for defined terms.

01/01/2011

Appendix 3Y Page 1

Appendix 3Y Change of Director’s Interest Notice

Part 2 – Change of director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder(if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interestrelated prior to changeNote: Details are only required for a contract in relation to which theinterest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/ConsiderationNote: If consideration is non-cash, provide details and an estimatedvaluation	N/A
Interest after change	N/A

3 –[+] Closed period Part

Were the interests in the securities or contractsdetailed above traded during a+closed periodwhere prior written clearance was required?	No
If so, was prior written clearance provided toallow the trade to proceed during this period?	N/A
If prior written clearance was provided, on whatdate was this provided?	N/A

• See chapter 19 for defined terms.

01/01/2011

Appendix 3Y Page 2